KRAS and neoplasm: Also during 2022, the new ligands that selectively bind to KRAS G12D, G12S, and G12R mutants have been developed, renewing the frontier to target alleles-specific hotspot mutations of KRAS.506 The G12D inhibitor exhibits encouraging antitumor efficacy in PDAC tumor models38 and G12S/R inhibitors provide proof of concept approaches to inspire the future development of other KRAS mutants.